Antiangiogenic therapy

Daniel Albo, Thomas N. Wang, George P. Tuszynski

Research output: Contribution to journalReview article

12 Citations (Scopus)

Abstract

Angiogenesis, the formation of blood vessels from preexisting ones, plays a crucial role in tumor progression. Activation of an "angiogenic switch" allows tumor cells to invade and metastasize. The growing interest in the use of antiangiogenic agents in the treatment and prevention of cancer lies in the theoretical advantages of this molecularly targeted modality of chemotherapy. Delivery of antiangiogenic agents are not complicated by having to penetrate large bulky masses but, instead, have easy access to tumoral endothelial cells. Antiangiogenic drugs may not cause cytopenias and thus will avoid many of the unwarranted toxicities of standard chemotherapeutic agents. Because they act directly on nascent endothelial cells, antiangiogenic agents may avoid tumor resistance mechanisms. If antiangiogenic agentsare successful, they might be applicable to many tumor types and not be dependent on cell type or growth fraction of cells within a tumor. However, several important obstacles remain with regards to using antiangiogenic drugs in clinical trials with which we must contend in order to determine accurately the efficacy of these agents. In-this article, we review the different classes of antiangiogenic agents available, ongoing clinical trials, as well as potential and future directions in this exciting field.

Original languageEnglish (US)
Pages (from-to)27-37
Number of pages11
JournalCurrent Pharmaceutical Design
Volume10
Issue number1
DOIs
StatePublished - Jan 22 2004

Fingerprint

Angiogenesis Inhibitors
Neoplasms
Therapeutics
Endothelial Cells
Clinical Trials
Pharmaceutical Preparations
Blood Vessels
Drug Therapy
Growth

Keywords

  • Angiogenesis
  • Antiangiogenesis
  • Antiangiogenic
  • Antiangiogenic agents
  • Antiangiogenic therapy
  • Chemoprevention

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery

Cite this

Antiangiogenic therapy. / Albo, Daniel; Wang, Thomas N.; Tuszynski, George P.

In: Current Pharmaceutical Design, Vol. 10, No. 1, 22.01.2004, p. 27-37.

Research output: Contribution to journalReview article

Albo, D, Wang, TN & Tuszynski, GP 2004, 'Antiangiogenic therapy', Current Pharmaceutical Design, vol. 10, no. 1, pp. 27-37. https://doi.org/10.2174/1381612043453522
Albo, Daniel ; Wang, Thomas N. ; Tuszynski, George P. / Antiangiogenic therapy. In: Current Pharmaceutical Design. 2004 ; Vol. 10, No. 1. pp. 27-37.
@article{25ed96bea54742659daa539bdf06113b,
title = "Antiangiogenic therapy",
abstract = "Angiogenesis, the formation of blood vessels from preexisting ones, plays a crucial role in tumor progression. Activation of an {"}angiogenic switch{"} allows tumor cells to invade and metastasize. The growing interest in the use of antiangiogenic agents in the treatment and prevention of cancer lies in the theoretical advantages of this molecularly targeted modality of chemotherapy. Delivery of antiangiogenic agents are not complicated by having to penetrate large bulky masses but, instead, have easy access to tumoral endothelial cells. Antiangiogenic drugs may not cause cytopenias and thus will avoid many of the unwarranted toxicities of standard chemotherapeutic agents. Because they act directly on nascent endothelial cells, antiangiogenic agents may avoid tumor resistance mechanisms. If antiangiogenic agentsare successful, they might be applicable to many tumor types and not be dependent on cell type or growth fraction of cells within a tumor. However, several important obstacles remain with regards to using antiangiogenic drugs in clinical trials with which we must contend in order to determine accurately the efficacy of these agents. In-this article, we review the different classes of antiangiogenic agents available, ongoing clinical trials, as well as potential and future directions in this exciting field.",
keywords = "Angiogenesis, Antiangiogenesis, Antiangiogenic, Antiangiogenic agents, Antiangiogenic therapy, Chemoprevention",
author = "Daniel Albo and Wang, {Thomas N.} and Tuszynski, {George P.}",
year = "2004",
month = "1",
day = "22",
doi = "10.2174/1381612043453522",
language = "English (US)",
volume = "10",
pages = "27--37",
journal = "Current Pharmaceutical Design",
issn = "1381-6128",
publisher = "Bentham Science Publishers B.V.",
number = "1",

}

TY - JOUR

T1 - Antiangiogenic therapy

AU - Albo, Daniel

AU - Wang, Thomas N.

AU - Tuszynski, George P.

PY - 2004/1/22

Y1 - 2004/1/22

N2 - Angiogenesis, the formation of blood vessels from preexisting ones, plays a crucial role in tumor progression. Activation of an "angiogenic switch" allows tumor cells to invade and metastasize. The growing interest in the use of antiangiogenic agents in the treatment and prevention of cancer lies in the theoretical advantages of this molecularly targeted modality of chemotherapy. Delivery of antiangiogenic agents are not complicated by having to penetrate large bulky masses but, instead, have easy access to tumoral endothelial cells. Antiangiogenic drugs may not cause cytopenias and thus will avoid many of the unwarranted toxicities of standard chemotherapeutic agents. Because they act directly on nascent endothelial cells, antiangiogenic agents may avoid tumor resistance mechanisms. If antiangiogenic agentsare successful, they might be applicable to many tumor types and not be dependent on cell type or growth fraction of cells within a tumor. However, several important obstacles remain with regards to using antiangiogenic drugs in clinical trials with which we must contend in order to determine accurately the efficacy of these agents. In-this article, we review the different classes of antiangiogenic agents available, ongoing clinical trials, as well as potential and future directions in this exciting field.

AB - Angiogenesis, the formation of blood vessels from preexisting ones, plays a crucial role in tumor progression. Activation of an "angiogenic switch" allows tumor cells to invade and metastasize. The growing interest in the use of antiangiogenic agents in the treatment and prevention of cancer lies in the theoretical advantages of this molecularly targeted modality of chemotherapy. Delivery of antiangiogenic agents are not complicated by having to penetrate large bulky masses but, instead, have easy access to tumoral endothelial cells. Antiangiogenic drugs may not cause cytopenias and thus will avoid many of the unwarranted toxicities of standard chemotherapeutic agents. Because they act directly on nascent endothelial cells, antiangiogenic agents may avoid tumor resistance mechanisms. If antiangiogenic agentsare successful, they might be applicable to many tumor types and not be dependent on cell type or growth fraction of cells within a tumor. However, several important obstacles remain with regards to using antiangiogenic drugs in clinical trials with which we must contend in order to determine accurately the efficacy of these agents. In-this article, we review the different classes of antiangiogenic agents available, ongoing clinical trials, as well as potential and future directions in this exciting field.

KW - Angiogenesis

KW - Antiangiogenesis

KW - Antiangiogenic

KW - Antiangiogenic agents

KW - Antiangiogenic therapy

KW - Chemoprevention

UR - http://www.scopus.com/inward/record.url?scp=0346656619&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0346656619&partnerID=8YFLogxK

U2 - 10.2174/1381612043453522

DO - 10.2174/1381612043453522

M3 - Review article

C2 - 14754403

AN - SCOPUS:0346656619

VL - 10

SP - 27

EP - 37

JO - Current Pharmaceutical Design

JF - Current Pharmaceutical Design

SN - 1381-6128

IS - 1

ER -